Detail akcie Lantern Pharma Rg online

Business Summary: Lantern Pharma Inc. is an artificial intelligence (AI) company. The Company is developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 100 billion oncology-focused data points and a library of over 200+ advanced ML algorithms to help solve problems in oncology drug development. It is engaged in the development of its pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody drug conjugate (ADC) program. It has active clinical programs for its three lead small molecule drug candidates: LP-300, LP-184, and LP-284. These programs are focused on multiple cancer indications, including both solid tumors and blood cancers. It is also focused on the clinical execution of its therapies for CNS and brain cancers through Starlight Therapeutics Inc.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Lantern Pharma Inc revenues was not reported. Net loss decreased 12% to $13M. Lower net loss reflects Pharmaceutical segment loss decrease of 16% to $13.8M. Basic Earnings per Share excluding Extraordinary Items increased from -$1.39 to -$1.21.